<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04145700</url>
  </required_header>
  <id_info>
    <org_study_id>17306</org_study_id>
    <secondary_id>J1S-MC-JV02</secondary_id>
    <secondary_id>2018-004243-23</secondary_id>
    <nct_id>NCT04145700</nct_id>
  </id_info>
  <brief_title>CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma</brief_title>
  <official_title>A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to test the safety and efficacy of ramucirumab in combination
      with other chemotherapy in the treatment of relapsed, recurrent, or refractory synovial
      sarcoma (SS) in children and young adults. This trial is part of the CAMPFIRE master protocol
      which is a platform to accelerate the development of new treatments for pediatric and young
      adult participants with cancer. Your participation in this trial could last 12 months or
      longer, depending on how you and your tumor respond.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2020</start_date>
  <completion_date type="Anticipated">July 13, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 12, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline to Objective Progression or Death Due to Any Cause (Estimated up to 12 Months)]</time_frame>
    <description>PFS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 12 Months)</time_frame>
    <description>ORR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up to 12 Months)</time_frame>
    <description>DoR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR): Percentage of Participants Who Achieve CR</measure>
    <time_frame>Baseline to date of CR (Estimated up to 12 Months)</time_frame>
    <description>CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax)</measure>
    <time_frame>Cycle 1 through Cycle 13 (21 Day Cycles)</time_frame>
    <description>PK: Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Minimum Concentration (Cmin)</measure>
    <time_frame>Cycle 1 through Cycle 13 (21 Day Cycles)</time_frame>
    <description>PK: Cmin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-Ramucirumab Antibodies</measure>
    <time_frame>Baseline through End of Study (Estimated up to 12 Months)</time_frame>
    <description>Number of Participants with Anti-Ramucirumab Antibodies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Synovial Sarcoma</condition>
  <arm_group>
    <arm_group_label>Ramucirumab + Gemcitabine + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramucirumab, Gemcitabine and Docetaxel given intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine + Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine and Docetaxel given IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramucirumab</intervention_name>
    <description>Ramucirumab given IV</description>
    <arm_group_label>Ramucirumab + Gemcitabine + Docetaxel</arm_group_label>
    <other_name>LY3009806</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine given IV</description>
    <arm_group_label>Gemcitabine + Docetaxel</arm_group_label>
    <arm_group_label>Ramucirumab + Gemcitabine + Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel given IV</description>
    <arm_group_label>Gemcitabine + Docetaxel</arm_group_label>
    <arm_group_label>Ramucirumab + Gemcitabine + Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have discontinued all previous treatments for cancer or
             investigational agents ≥7 days after the last dose or per the type of previous
             treatment as stated in the protocol and must have recovered from the acute effects to
             ≤Grade 2 for alopecia and decreased tendon reflex and to ≤Grade 1 for all other
             effects at the time of enrollment, unless otherwise noted. Consult with the Lilly
             clinical research physician or scientist for the appropriate length of time prior to
             the first dose of study treatment.

          -  Participants with relapsed, recurrent, or refractory SS.

          -  Participants must:

               -  Have measurable disease by Response Evaluation Criteria in Solid Tumors, Version
                  (RECIST) 1.1.

               -  have received at least one prior line of systemic treatment (including
                  neoadjuvant and adjuvant chemotherapy) that contains ifosfamide and/or
                  doxorubicin, or any approved therapies for which they are eligible, unless the
                  patient is not a suitable candidate for the approved therapy.

               -  not be eligible for surgical resection at time of enrollment.

          -  Adequate cardiac function, defined as: Shortening fraction of ≥27% by echocardiogram,
             or ejection fraction of ≥50% by gated radionuclide study.

          -  Adequate blood pressure (BP) control, defined as:

               -  Participants ≥18 years: Controlled hypertension defined as systolic BP ≤150
                  millimeters of mercury (mmHg) or diastolic BP ≤90 mmHg where standard medical
                  management is permitted. Please note that ≥2 serial BP readings should be
                  obtained and averaged to determine baseline BP.

               -  Participants &lt;18 years: A BP ≤95th percentile for age, height, and gender
                  measured as described in National High Blood Pressure Education Program Working
                  Group (NHBPEPWG) on High Blood Pressure in Children and Adolescents (2004), where
                  standard medical management is permitted. Please note that ≥2 serial BP readings
                  should be obtained and averaged to determine baseline BP.

          -  Adequate hematologic function, as defined as:

               -  Absolute neutrophil count (ANC): ≥750/microliters (µL) granulocyte-colony
                  stimulating factor (G-CSF) permitted up to 48 hours prior. Participants with
                  documented history of benign ethnic neutropenia or other conditions could be
                  considered with a lower ANC after discussion with and approval from the Lilly
                  clinical research physician or scientist.

               -  Platelets: ≥75,000/cubic millimeters. Platelet transfusion permitted up to 72
                  hours prior.

               -  Hemoglobin: ≥8 grams per deciliter (g/dL) (≥80 g/liter). Transfusions to increase
                  the participant's hemoglobin level to at least 8 g/dL are permitted; however,
                  study treatment must not begin until 7 days after the transfusion, and complete
                  blood count criteria for eligibility are confirmed within 24 hr of first study
                  dose.

          -  Adequate renal function, as defined as:

               -  Creatinine clearance or radioscope glomerular filtration rate (GFR) ≥60
                  milliliters/minute/meters squared OR serum creatinine meeting the following
                  parameters:

                    -  for participants ≥18 years of age serum creatinine ≤1.5×upper limit of
                       normal (ULN);

                    -  for participants &lt;18 years of age, serum creatinine based on age/gender as
                       follows: Age 1 to &lt;2 years maximum serum creatinine 0.6, Age 2 to &lt;6 years
                       maximum serum creatinine 0.8, Age 6 to &lt;10 years maximum serum creatinine
                       1.0, Age 10 to &lt;13 years maximum serum creatinine 1.2, Age 13 to &lt;16 years
                       maximum serum creatinine 1.5 for males and 1.4 for females, Age 16 to &lt;18
                       years maximum serum creatinine 1.7 for males and 1.4 for females.

               -  Urine protein meeting the following parameters:

                    -  for participants ≥18 years of age: &lt;2+ on dipstick or routine urinalysis. If
                       urine dipstick or routine analysis indicates proteinuria ≥2+, then a 24-hour
                       urine must be collected and must demonstrate &lt;2 grams of protein in 24 hours
                       to allow participation in the study.

                    -  for participants &lt;18 years of age: ≤30 milligrams per deciliter urine
                       analysis or &lt;2+ on dipstick. If urine dipstick or routine analysis indicates
                       proteinuria ≥2+, then a 24-hour urine must be collected and must demonstrate
                       &lt;1 g of protein in 24 hours to allow participation in the study.

          -  Adequate liver function:

               -  Total bilirubin: ≤1.5×ULN. Except participants with document history of Gilbert
                  Syndrome who must have a total bilirubin level of &lt;3.0×ULN.

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST): ≤2.5×ULN OR
                  ≤5.0×ULN if the liver has tumor involvement.

          -  The participant has an adequate coagulation function as defined by International
             Normalized Ratio ≤1.5 or prothrombin time ≤1.5×ULN, and partial thromboplastin time
             ≤1.5×ULN if not receiving anticoagulation therapy. For participants receiving
             anticoagulants, exceptions to these coagulation parameters are allowed if they are
             within the intended or expected range for their therapeutic use. Participants must
             have no history of clinically significant active bleeding (defined as within 14 days
             of first dose of study drug) or pathological condition that carries a high risk of
             bleeding (for example, tumor involving major vessels or known esophageal varices).

          -  The participant has adequate hematologic and organ function ≤1 week (7 days) prior to
             first dose of study drug.

          -  Female participants of childbearing potential must have a negative urine or serum
             pregnancy test within 7 days prior to randomization. Male and female participants must
             agree to use highly effective contraception for the duration of the study and up to 3
             months following the last dose of ramucirumab and 6 months following the last dose of
             docetaxel and gemcitabine in order to prevent pregnancy.

        Exclusion Criteria:

          -  Participants with severe and/or uncontrolled concurrent medical disease or psychiatric
             illness/social situation that in the opinion of the investigator could cause
             unacceptable safety risks or compromise compliance with the protocol.

          -  Participants who have active infections requiring therapy.

               -  Participants with an active fungal, bacterial, and/or known severe viral
                  infection including, but not limited to, human immunodeficiency virus (HIV) or
                  viral (A, B, or C) hepatitis (screening is not required).

          -  Participants who have had allogeneic bone marrow or solid organ transplant are
             excluded.

          -  Surgery: Participants who have had, or are planning to have, the following invasive
             procedures are not eligible:

               -  Major surgical procedure, laparoscopic procedure, or significant traumatic injury
                  within 28 days prior to enrollment.

               -  Central line placement or subcutaneous port placement is not considered major
                  surgery.

               -  Core biopsy, fine needle aspirate, and bone marrow biopsy/aspirate are not
                  considered major surgeries.

               -  Surgical or other wounds must be adequately healed prior to enrollment.

          -  Bleeding and thrombosis:

               -  Participants with evidence of active bleeding or a history of significant (≥Grade
                  3) bleeding event within 3 months prior to enrollment are not eligible.

               -  Participants with a bleeding diathesis or vasculitis are not eligible.

               -  Participants with known or prior history in the prior 3 months of esophageal
                  varices are not eligible.

               -  Participants with a history of deep vein thrombosis requiring medical
                  intervention (including pulmonary embolism) within 3 months prior to study
                  enrollment are not eligible.

               -  Participants with a history of hemoptysis or other signs of pulmonary hemorrhage
                  within 3 months prior to study enrollment are not eligible.

          -  Cardiac:

               -  Participants with a history of central nervous system (CNS) arterial/venous
                  thromboembolic events (VTEs) including transient ischemic attack (TIA) or
                  cerebrovascular accident (CVA) within 6 months prior to study enrollment are not
                  eligible.

               -  Participants with myocardial infarction or unstable angina within the prior 6
                  months.

               -  Participants with New York Heart Association Grade 2 or greater congestive heart
                  failure (CHF).

               -  Participants with serious and inadequately controlled cardiac arrhythmia.

               -  Participants with significant vascular disease (eg, aortic aneurysm, history of
                  aortic dissection).

               -  Participants with clinically significant peripheral vascular disease.

          -  Participants who have a history of fistula, gastrointestinal (GI) ulcer or
             perforation, or intra-abdominal abscess within 3 months of study enrollment are not
             eligible.

          -  Participants with a history of hypertensive crisis or hypertensive encephalopathy
             within 6 months of study enrollment are not eligible.

          -  Participants who have non-healing wound, unhealed or incompletely healed fracture, or
             a compound (open) bone fracture at the time of enrollment are not eligible.

          -  Participants previously treated and progressed on combination gemcitabine and
             docetaxel regimen. Participants who received combination as maintenance therapy,
             without progression, would be eligible.

          -  Participants with a known hypersensitivity to ramucirumab, gemcitabine, docetaxel, or
             agents formulated with Polysorbate 80.

          -  Hepatic impairment:

               -  Severe liver cirrhosis Child-Pugh Class B (or worse).

               -  Cirrhosis with a history of hepatic encephalopathy.

               -  Clinically meaningful ascites resulting from cirrhosis and requiring ongoing
                  treatment with diuretics and/or paracentesis.

               -  History of hepatorenal syndrome.

          -  The participant has a bowel obstruction, history or presence of inflammatory
             enteropathy or extensive intestinal resection (eg, hemicolectomy or extensive small
             intestine resection with chronic diarrhea), Crohn's disease, ulcerative colitis, or
             chronic diarrhea.

          -  The participant has symptomatic interstitial pneumonia or pulmonary fibrosis (or
             consistent findings of interstitial pneumonia/pulmonary fibrosis on imaging).

          -  Participants with central nervous system (CNS) involvement are ineligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>Clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Childrens Hospital of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gregory Friedman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>323-669-2101</phone>
    </contact>
    <investigator>
      <last_name>Winston Huh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Noah Federman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Josephine HaDuong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>AeRang Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic-Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>904-953-6131</phone>
    </contact>
    <investigator>
      <last_name>Steven Attia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>312-227-4834</phone>
    </contact>
    <investigator>
      <last_name>David Walterhouse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>317-944-1900</phone>
    </contact>
    <investigator>
      <last_name>Melissa Bear</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Natalie Collins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>612-626-3593</phone>
    </contact>
    <investigator>
      <last_name>Emily Greengard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University Medical School</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>314-286-2584</phone>
    </contact>
    <investigator>
      <last_name>Brian A Van Tine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Emily Slotkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andrew Bukowinski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>241-648-4948</phone>
    </contact>
    <investigator>
      <last_name>Theodore W Laetsch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>713-745-6754</phone>
    </contact>
    <investigator>
      <last_name>Pooja Hingorani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital Research Foundation</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>206-987-2114</phone>
    </contact>
    <investigator>
      <last_name>Catherine Albert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61290365375</phone>
    </contact>
    <investigator>
      <last_name>Vivek Bhadri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Sydney Children's Hospitals Network</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61298452138</phone>
    </contact>
    <investigator>
      <last_name>Jessica Ryan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61385598339</phone>
    </contact>
    <investigator>
      <last_name>Jeremy Lewin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Childrens Hospital Melbourne</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61385595000</phone>
    </contact>
    <investigator>
      <last_name>Lisa Orme</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>3293324812</phone>
    </contact>
    <investigator>
      <last_name>Bram De Wilde</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCL- Saint Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>3227642376</phone>
    </contact>
    <investigator>
      <last_name>Benedicte Brichard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33547306088</phone>
    </contact>
    <investigator>
      <last_name>Antoine Italiano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Leon Berard</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33478785126</phone>
    </contact>
    <investigator>
      <last_name>Jean Yves Blay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris CEDEX 05</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33144324068</phone>
    </contact>
    <investigator>
      <last_name>Sophie Piperno-Neumann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>4976127043010</phone>
    </contact>
    <investigator>
      <last_name>Simone Hettmer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>4930450666488</phone>
    </contact>
    <investigator>
      <last_name>Anne Thorwarth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>492017232255</phone>
    </contact>
    <investigator>
      <last_name>Uta Dirksen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg - Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>4940741020622</phone>
    </contact>
    <investigator>
      <last_name>Andreas Block</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <state>Lombardie</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>390223903062</phone>
    </contact>
    <investigator>
      <last_name>Andrea Ferrari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>390282244599</phone>
    </contact>
    <investigator>
      <last_name>Alexia Francesca Bertuzzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Piemonte l'Oncologia-Istituto Ricerca Cura Cancro</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>390119933278</phone>
    </contact>
    <investigator>
      <last_name>Massimo Aglietta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>390498215493</phone>
    </contact>
    <investigator>
      <last_name>Gianni Bisogno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-Ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120360605</phone>
    </contact>
    <investigator>
      <last_name>Chitose Ogawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>812 8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+81120023812</phone>
    </contact>
    <investigator>
      <last_name>Yuki Koga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>31715263459</phone>
    </contact>
    <investigator>
      <last_name>A.J. (Hans) Gelderblom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prinses Maxima Centrum</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>31650006353</phone>
    </contact>
    <investigator>
      <last_name>Natasha van Eijkelenburg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34955923113</phone>
    </contact>
    <investigator>
      <last_name>Javier Martin Broto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34935537116</phone>
    </contact>
    <investigator>
      <last_name>Antonio López-Pousa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34932746100</phone>
    </contact>
    <investigator>
      <last_name>Claudia Maria Valverde Morales</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34922678204</phone>
    </contact>
    <investigator>
      <last_name>Josefina Cruz Jurado</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34917277516</phone>
    </contact>
    <investigator>
      <last_name>Andrés Redondo Sanchez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College Hospital - London</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>442034479346</phone>
    </contact>
    <investigator>
      <last_name>Sandra Strauss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>01614463000</phone>
    </contact>
    <investigator>
      <last_name>Martin McCabe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>020 7352 8171</phone>
    </contact>
    <investigator>
      <last_name>Spyridon Gennatas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M139WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00441617018430</phone>
    </contact>
    <investigator>
      <last_name>Bernadette Brennan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/4Kdc8Gc0Rx6Z00sohuB8vD?conditionId=2QRo8xuXMskaAqWYmuMWcQ</url>
    <description>CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma</description>
  </link>
  <verification_date>July 1, 2020</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>soft tissue sarcoma</keyword>
  <keyword>adolescents and young adults (AYAs)</keyword>
  <keyword>adolescent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Synovial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Ramucirumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

